Atossa Therapeutics (NASDAQ:ATOS) Given New $7.00 Price Target at HC Wainwright

Atossa Therapeutics (NASDAQ:ATOS) had its price objective hoisted by HC Wainwright from $6.00 to $7.00 in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Atossa Therapeutics’ FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($0.27) EPS and FY2028 earnings at ($0.21) EPS.

Several other analysts have also commented on the stock. StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 8th. Ascendiant Capital Markets boosted their price target on Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a research report on Wednesday, September 11th.

Atossa Therapeutics Price Performance

Shares of NASDAQ:ATOS opened at $1.28 on Wednesday. The stock has a market cap of $160.97 million, a P/E ratio of -5.82 and a beta of 1.23. Atossa Therapeutics has a 1-year low of $0.65 and a 1-year high of $2.31. The firm has a fifty day moving average price of $1.44 and a 200 day moving average price of $1.38.

Institutional Investors Weigh In On Atossa Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Atossa Therapeutics by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after acquiring an additional 78,269 shares during the period. Virtu Financial LLC acquired a new position in shares of Atossa Therapeutics during the first quarter valued at about $151,000. Cetera Advisors LLC bought a new position in Atossa Therapeutics in the first quarter worth $72,000. Bank of New York Mellon Corp boosted its holdings in Atossa Therapeutics by 3,160.5% during the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after purchasing an additional 399,041 shares in the last quarter. Finally, Rhumbline Advisers acquired a new position in shares of Atossa Therapeutics in the 2nd quarter worth approximately $161,000. 12.74% of the stock is currently owned by institutional investors.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.